All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
Bookmark this article
On 14th September 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to copanlisib for the treatment of adult patients with relapsed Follicular Lymphoma (FL) who have received two or more systemic therapies.
The accelerated approval for Bayer’s PI3K inhibitor is based on findings from the single-arm, phase II CHRONOS-1 trial (NCT01660451), which included 104 FL patients who had experienced relapse after at least two previous systemic therapies. Results of this pivotal trial were presented during the 14th International Conference on Malignant Lymphoma (ICML) by Martin Dreyling from the University Hospital of Munich, Germany; click here to read more on this abstract presentation.
Professor Anas Younes from Memorial Sloan Kettering Cancer Center, and Co-Chair of the Lymphoma Hub Executive Steering Committee, said in the press release: “When treating patients with relapsed Follicular Lymphoma, two factors for physicians involve lessening tumor burden and reducing adverse events (AEs) patients may experience from treatments. Therapies need to be both effective and tolerable.” Professor Younes went on to say “The PI3K pathway is activated in many tumor types, including lymphoma, and targeting PI3K therapeutically is a very important strategy in this area of disease. Copanlisib has a safety and efficacy profile that is a welcome advance for both doctors and patients in third-line Follicular Lymphoma.”
Copanlisib has also been awarded Orphan Drug Designation by the FDA for patients with Marginal Zone Lymphoma (MZL).
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox